LOGIN
Denosumab increases BMD and reduces bone turnover vs monthly oral bisphosphonate
December 2016
Denosumab increases BMD and reduces bone turnover vs monthly oral bisphosphonate
Study Type:Randomized Trial
OE Level Evidence:2
Journal Level of Evidence:N/A
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis
Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
A post hoc analysis was performed combining the data from two previously conducted randomized controlled trials (RCTs) in postmenopausal women (total of 1705 patients) with low adherence to a daily/weekly BP treatment who then transitioned to either denosumab or a monthly BP treatment (ibandronate and risedronate, respectively). This study aimed to compare bone mineral density and bone turnover ma...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.